We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Role of TGF- β in Mesangial Matrix Accumulation in Chronic Progressive Glomerular Disease

Hyun Soon Lee

Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

1. Introduction

Lesions of focal segmental glomerulosclerosis (FSGS) are a pathological hallmark of progressive glomerular injury. Glomerulosclerosis frequently complicates most renal diseases, and is characterized by the collapse of the glomerular tuft with the accumulation of mesangial matrix. Transforming growth factor- β (TGF- β) is a key regulator of extracellular matrix (ECM) protein synthesis in renal cells. TGF- β is secreted as latent complexes, which are stored in the ECM to provide stability to the active molecule and a readily activable source of it (Lawrence 2001). Overexpression of active TGF- β 1 in transgenic mice causes mesangial expansion and thickened capillary loops in the glomeruli (Kopp et al. 1996), while monoclonal antibody to TGF- β reduces the glomerulosclerosis in experimental proliferative glomerulonephritis (GN) (Yu et al. 2004) and diabetic nephropathy (Benigni et al. 2003; Ziyadeh et al. 2000).

Cultured mesangial cells secrete TGF- β and ECM proteins in response to various fibrogenic stimuli (Kim et al. 2001; Lee et al. 2004; Lee and Song 2009a; Ziyadeh et al. 1994, 1998). In chronic mesangial diseases, such as IgA nephropathy (IgAN) and diabetic nephropathy, TGF- β 1 mRNA expression by mesangial cells is increased, yet mesangial immunostaining for active TGF- β 1 is frequently negative (Kim et al. 2002; Stein-Oakley et al. 1997; Wahab et al. 2005). Only podocytes covering the sclerotic segments exhibit increased expression of TGF- β 1 protein (Kim et al. 2002; Wahab et al. 2005). These findings suggest that mesangial cells secrete latent TGF- β in chronic mesangial disease, which may be localized to the podocyte surface to be activated (Lee and Song 2009b).

Podocytes are the target of injury in most glomerular diseases. Expression of TGF- β mRNA and/or protein by podocytes is increased in progressive podocyte diseases, such as primary FSGS, membranous nephropathy, Alport syndrome and Denys-Drash syndrome (Kim et al. 2003; Kim et al. 1999; Patek et al. 2003; Sayers et al. 1999; Shankland et al. 1996). In addition, mesangial matrix is frequently increased in association with glomerulosclerosis (Gregory et al. 1996; Lee and Koh 1993; Lee and Lim 1995; Kim et al. 1995; Patek et al. 2003). Thus, TGF- β , that is expressed and/or activated by podocytes, may contribute to mesangial matrix oversynthesis in both chronic mesangial disease and podocyte disease (Lee 2011).

This review will discuss the recent findings on the mechanisms and consequences of latent TGF- β activation and TGF- β -induced mesangial matrix accumulation in chronic progressive glomerular disease.

2. Structure of mesangial cells

Glomerular mesangial cells together with their surrounding matrix constitute the mesangium, a structure that is separated from the capillary lumen by the endothelium. The mesangial cells are surrounded by mesangial matrix, that is similar but not identical to the peripheral glomerular basement membrane (GBM). The mesangial matrix contains type IV collagen, sulfated glycosaminoglycans, fibronectin and laminin. The mesangial cells are often compared with vascular smooth muscle cells, and are able to proliferate and produce excessive matrix proteins when stimulated.

3. Chronic progressive glomerular diseases with TGF- β overexpression in podocytes

3.1 IgAN

The diagnosis of IgAN is based on the demonstration of predominant or codominant IgA deposition in the mesangium. The glomerular histopathology mainly represents the mesangial lesions showing cell proliferation and/or matrix expansion. In addition, focal abnormalities of the GBM are sometimes present, with reticulation, thinning and thickening, as well as subepithelial deposits (Lee et al. 1987, 1989). Up to 30% of patients with IgAN eventually progress to end-stage renal disease (ESRD) after a follow-up of 25 years (Ibels and Györy 1994). The more severe glomerular lesions, which have higher percentage of glomerulosclerosis and crescents, are significantly related to progressive IgAN (El Karoui et al. 2011; Lee et al. 2005). Other glomerular lesions, such as mesangial hyperplasia and endocapillary lesions, also contribute to worse prognosis (Working Group of the International IgA Nephropathy Network 2010).

The intensity of immunostaining for platelet-derived growth factor, type IV collagen, laminin, and fibronectin is increased in the mesangium in renal biopsies with IgAN (Kim et al. 2002). In the early stage of IgAN with mesangial cell proliferation, some mesangial cells show immunoreactivity for TGF- β 1 (Stein-Oakley et al. 1997). Mesangial immunostaining for active TGF- β 1, however, is very weak or almost negligible in most human IgAN, despite increased mesangial TGF- β 1 mRNA levels. Instead, hyperplastic podocytes covering the sclerotic segments exhibit increased expression of TGF- β 1 protein (Kim et al. 2002).

Mesangial expression of TGF- β isoforms is transiently upregulated in acute anti-Thy1.1 nephritis, a rodent model of mesangial proliferative GN (Hartner et al. 2003; Ito et al. 2001; Liu et al. 2004), in which TGF- β 1 expression is only segmentally and weakly distributed (Ito et al. 2001).

3.2 Primary FSGS

Primary FSGS is a clinicopathologic entity characterized by nephrotic syndrome and progression to ESRD. Intrarenal transcription of TGF- β 1 is increased in children with FSGS compared to those with minimal lesion, suggesting that TGF- β 1 gene transcription is indicative of progressive renal damage typical of FSGS (Strehlau et al. 2002). Expression of TGF- β 1 is increased in patients with primary FSGS, particularly in podocytes of sclerotic segments (Kim et al. 2003). Volume density of mesangial matrix is significantly greater in the FSGS patients than in minimal lesion cases. In patients with FSGS, the percent glomerulosclerosis correlates directly with mesangial volume per glomerulus (Lee and Lim 1995).

3.3 The significance of FSGS formation in chronic glomerular disease

Some authors regarded FSGS as a nonspecific heterogeneous form of renal injury (Whitworth et al. 1978). The lesions of FSGS following primary glomerular diseases, such as IgAN and membranous nephropathy, have often been excluded in the category of secondary FSGS, because they were regarded as the nonspecific chronic scarred phase of the disease (D'Agati et al. 2004). Nonetheless, the lesions of FSGS in IgAN show immunohistochemical changes, which are basically identical to those described in primary FSGS, with loss of podocyte markers (Hill et al. 2011). Furthermore, podocytes covering the sclerotic segments exhibit enhanced expression of TGF- β 1 in IgAN and advanced diabetic nephropathy similar to those observed in primary FSGS. Thus, common podocyte lesions may contribute to the development of FSGS in both primary FSGS and other chronic glomerular diseases.

3.4 Membranous nephropathy

Membranous nephropathy is a well-characterized histological entity with a highly variable clinical course. Overall, approximately 30-40% of patients develop significant renal failure 10-15 years after the diagnosis of nephropathy (Perna et al. 2004). New genomewide association study suggests that sequence variations within HLA and receptor for phospholipase A2 are responsible in part for the development of idiopathic membranous nephropathy (Stanescu et al. 2011). The hallmark of membranous nephropathy is the presence of glomerular subepithelial deposits that typically contain immunoglobulin and complement component. Between and around these deposits, the GBM is thickened due to the accumulation of GBM material, forming subepithelial projections or spikes. Complement membrane attack complex (C5b-C9) plays an important role in the development of podocyte injury and proteinuria in passive Heymann nephritis (PHN), an experimental model of human membranous nephropathy (Couser and Nangaku 2006). Upregulation of TGF- β 1 and GBM protein mRNAs by podocytes is shown in patients with membranous nephropathy (Kim et al. 1999). Expression of TGF- β 2 is also markedly increased in podocytes in experimental membranous nephropathy, together with upregulation of TGF- β receptors (Shankland et al. 1996).

Lesions of FSGS are observed in 43% of the membranous nephropathy patients, in whom the degree of mesangial expansion and GBM thickening is significantly greater than the remaining cases without FSGS (Lee and Koh 1993). In PHN, mesangial volume was also significantly elevated, together with GBM thickening (Remuzzi et al. 1999).

3.5 Diabetic nephropathy

Diabetic nephropathy remains the most common cause for ESRD as the burden of diabetes increases worldwide. Nearly one-third of patients with diabetes develop nephropathy (Choudhury et al. 2010). Mesangial matrix expansion and thickening of the GBM are hallmarks of diabetic nephropathy, which occur even within a few years after the onset of type 1 diabetes (Drummond and Mauer 2002). If left untreated, 20-40% of patients with type 2 diabetes show progression to renal failure (Adler et al. 2003; Remuzzi et al. 2002).

In the early stage of human diabetic nephropathy, some mesangial cells show immunoreactivity for TGF- β 1. Yet mesangial immunostaining for active TGF- β 1 is very weak or almost negligible in most human diabetic nodular glomerulosclerosis, despite increased mesangial TGF- β 1 mRNA levels. Rather, podocytes covering the sclerotic

segments show increased expression of TGF- β 1 mRNA and protein (Wahab et al. 2005). In the glomeruli of experimental diabetic nephropathy, only a few cells show positive immunostaining for TGF- β 1 (Hill et al. 2000). Enhanced expression of glomerular TGF- β 1 is observed mainly in podocytes of diabetic animals (Baba et al. 2005; Okada et al. 2006).

3.6 Alport renal disease

Collagen type IV is the main component of the GBM, which includes six genetically distinct isoforms named α 1(IV) to α 6(IV). The α 3- α 5(IV) chains originate solely from podocytes in both the developing and mature glomerulus (Abrahamson et al. 2009). The α 1/ α 2(IV) collagen network, by contrast, seems to originate mainly from glomerular endothelial cells (Lee et al. 1993), and is localized predominantly at the endothelial aspect of human GBM (Zhang and Lee 1997).

Alport syndrome is primary genetic disease of the basement membrane. In the kidney, this disorder is characterized by an absence of collagen α 3 α 4 α 5(IV) in the GBM, progressive thickening and multilamination of the GBM, proteinuria, and renal failure. Yet collagen α 1/ α 2(IV) is retained throughout the GBM (Abrahamson et al. 2003; Kashtan et al. 2001). In podocytes of α 3(IV) collagen-knockout mice with Alport renal disease, mRNA expression of TGF- β 1 is increased (Sayers et al. 1999). With disease progression, mesangial matrix and cells are increased, followed by the development of glomerulosclerosis (Gregory et al. 1996; Kim et al. 1995).

3.7 Denys-Drash syndrome

Wilms' tumour suppressor gene, WT1, is essential for normal podocyte function. Mutations of WT1 induce Denys-Drash syndrome (DDS) characterized by diffuse mesangial sclerosis. In DDS mice, the development of glomerulosclerosis is preceded by de novo TGF- β 1 expression in podocytes, while TGF- β 1 expression is absent in the mesangium (Patek et al. 2003).

In summary, expression of TGF- β 1 by podocytes is increased not only in progressive podocyte disease but also in chronic mesangial disease. Despite mesangial matrix expansion in association with glomerulosclerosis in both types of disease, immunohistochemical antigen detection for mesangial TGF- β 1 seems to be difficult even in chronic mesangial disease.

4. Activation of latent TGF- β

TGF- β is secreted as latent complexes associated with a latency-associated peptide (LAP). TGF- β /LAP complex is referred to as the small latent complex. Most cells secrete TGF- β as part of a large latent complex, in which latent TGF- β binding protein (LTBP) is linked to the small latent complex. LTBP has a role in targeting the transport of latent TGF- β complex into the ECM (Hyytiäinen et al. 2004; Koli et al. 2008).

The large latent complex is susceptible to proteolysis, within which LTBP is first cleaved at the protease sensitive hinge region. The soluble large latent complex is then released from the ECM and is activated by another proteolytic event that releases TGF- β from LAP (Koli et al. 2001). The TGF- β released then binds to its receptor and exerts its cellular functions.

Under in vitro conditions, latent TGF- β is activated by heating, acid or alkaline treatment, irradiation, reactive oxygen species (ROS), proteases including plasmin, cathepsin, calpain, matrix metalloproteinase (MMP)-2 and MMP-9, some integrins, or thrombospondin-1 (TSP-1) (for review, see Koli et al. 2001).

Several activation mechanisms may exist in vivo as reviewed below (Table 1).

4.1 TGF-β activation by proteolysis

Plasmin could function as an in vivo activator of TGF-β (Lyons et al. 1990; Edgtton et al. 2004). Plasmin can release the large latent TGF-β complex from the ECM by cleaving LTBP at the amino terminal hinge region (Taipale et al. 1992). Furthermore, it can cleave LAP that releases active TGF-β dimer from the large latent TGF-β1 complex (Annes et al. 2003; George et al. 2005; Lyons et al. 1990).

MMP-2 and MMP-9 have also been implicated in the cleavage of LAP and the release of mature TGF-β at the cell surface (Yu and Stamenkovic 2000).

4.2 TSP-1-mediated activation of TGF-β

TSP-1 is known to be a major physiologic activator of latent TGF-β (Crawford et al. 1998). A specific peptide sequence within TSP-1, KRFK, binds to the LSKL sequence in LAP, and releases mature TGF-β by inducing conformational changes in the protein (Crawford et al. 1998; Lawrence 2001; Koli et al. 2008). However, it is not clear whether TSP-1 alone could directly activate latent TGF-β (Abdelouahed et al. 2000; Grainger and Frow 2000; Otsuka et al. 2007).

Overexpression of both TSP-1 and active TGF-β occurs in podocytes in patients with FSGS (Kim et al. 2003) and diabetic nephropathy (Wahab et al. 2005). In various experimental renal disease models, TSP-1 is co-localized with TGF-β and predicts the development of tissue fibrosis (Hugo et al. 1998).

4.3 ROS-mediated activation of TGF-β

ROS produced by ionizing radiation was found to induce rapid TGF-β activation in vivo (Barcellos-Hoff and Dix 1996). ROS can activate TGF-β directly through oxidation-induced conformational change in LAP, in which the unique methionine residue in the TGF-β1/LAP functions as a redox switch center (Jobling et al. 2006), or indirectly through the activation of proteolytic enzymes (Koli et al. 2008).

4.4 Integrins in TGF-β binding and activation

Integrins can bind to the RGD recognition domain in the LAP of TGF-β1 and TGF-β3. Particularly, αvβ6 and αvβ8 are known to activate the TGF-β complex (Munger et al. 1999; Mu et al. 2002), leading to release of TGF-β either by tractional force (αvβ6) or by membrane type-1 MMP (MT1-MMP)-dependent proteolytic activity (αvβ8) (Koli et al. 2008). By cell movement, an αvβ6-integrin-expressing cell causes sufficient traction for the release of mature TGF-β from the ECM-anchored large latent complex (Annes et al. 2004).

Activators		Mechanisms of action	1 st author
Plasmin	-	Proteolytic nicking of LTBP releasing large latent TGF-β complex from the ECM	Taipale (1992); Lyons (1990); Annes (2003); George (2005)
	-	Proteolytic nicking of the LAP	
TSP-1	-	Induction of conformational changes in LAP	Crawford(1998); Lawrence (2001); Koli (2008)
ROS	-	Induction of conformational changes in LAP	Jobling (2006); Koli (2008)
	-	Inducing activation of proteolytic enzymes	
Integrin, αvβ6	-	Release of TGF-β from LAP by tractional force	Annes (2004)

TGF-β, transforming growth factor-β; LTBP, latent TGF-β binding protein; ECM, extracellular matrix; TSP-1, thrombospondin-1; LAP, latency-associated peptide; ROS, reactive oxygen species.

Table 1. Proposed mechanisms for latent TGF-β activation in chronic glomerular disease

$\alpha\text{v}\beta 6$ integrin is expressed in the diseased kidneys confined to the distal tubules and collecting ducts (Trevillian et al. 2004). Deleting TGF- β type II receptor in collecting duct cells in vitro resulted in increased integrin $\alpha\text{v}\beta 6$ -dependent TGF- β activation, that increased collagen synthesis in co-cultured renal interstitial fibroblasts (Gewin et al. 2010).

5. Mechanism of TGF- β overexpression by podocytes in chronic glomerular disease

5.1 Incomplete activation of mesangial TGF- β in chronic mesangial disease

Intense mesangial immunostaining for LTBP-1 is observed in anti-Thy1.1 nephritis associated with severe but transient mesangial matrix accumulation (Porst et al. 2006). In rats with anti-Thy1.1 nephritis, active TGF- β 1-positive area/glomerulus was 18%, while treatment with antisense TSP-1 oligodeoxynucleotides reduced it to 9% (Daniel et al. 2003). In wild-type and TSP-1 deficient diabetic mice, the TGF- β 1-positive area in the glomerulus was 5% and 3%, respectively (Daniel et al. 2007). Thus, TSP-1 seems to activate mesangial TGF- β 1 more actively in acute mesangial proliferative GN than in chronic mesangial disease.

Plasmin can release the large latent TGF- β complex from the mesangial matrix by cleaving LTBP at the amino terminal hinge region (Taipale et al. 1992) (Fig. 1). The plasmin-mediated

Fig. 1. Incomplete activation of mesangial TGF- β in chronic mesangial disease. Upon fibrogenic stimuli, large latent TGF- β complex in association with latent TGF- β binding protein (LTBP) is synthesized and secreted from mesangial cells. It is then associated with mesangial matrix via N-terminus of LTBP. In protease-mediated activation of TGF- β , LTBP is first cleaved at the protease sensitive amino terminal hinge region, and soluble large latent complex is released.

TGF- β activation, however, may be neutralized via feedback inhibition, since TGF- β -induced production of plasminogen activator inhibitor-1 decreases the active plasmin formation in mesangial cells (Baricos et al. 2003). Furthermore, accumulation of mesangial matrix progressed in association with enhanced mesangial fibrin deposition in rats with anti-Thy 1.1 nephritis (Liu et al. 2004). Thus, the mesangial cell surface surrounded by an enlarged matrix may not express sufficient plasmin to further cleave LAP that liberates active TGF- β dimer from the large latent TGF- β 1 complex.

In view of the enhanced expression of TGF- β 1 in podocytes in human IgAN (Kim et al. 2002) and end-stage diabetic nephropathy (Wahab et al. 2005), podocytes seem to respond to paracrine TGF- β coming from the mesangium. Even though free active TGF- β is liberated from the mesangium, it has a very short half-life in plasma (2-3 min) (Coffey et al. 1987), in contrast to the latent TGF- β complex with a significantly longer half-life (>100 min) (Wakefield et al. 1990). Thus, soluble forms of large latent TGF- β complex, rather than active TGF- β , may be localized to the podocyte surface after its release from the mesangial matrix (Fig. 1 and 2).

Fig. 2. Hypothetical pathway for TGF- β activation by podocytes in the diseased glomeruli. Soluble large latent TGF- β complex coming from the mesangium in chronic mesangial disease (CMD) and biomechanical strain-induced TGF- β in progressive podocyte disease (PPD) may be the source of latent TGF- β complex in podocytes. It is then activated by angiotensin II (Ang II)/reactive oxygen species (ROS), plasmin, matrix metalloproteinases (MMPs) and thrombospondin-1 (TSP-1). Active TGF- β , which is released from latency-associated peptide, is able to associate with the signaling receptors (TGF- β R'), and signal transduction pathway is activated.

5.2 Induction of podocyte TGF- β by glomerular hypertension or biomechanical strain in progressive podocyte disease

In progressive podocyte diseases, TGF- β expression is increased in podocytes (Kim et al. 1999, 2003; Patek et al. 2003; Sayers et al. 1999; Shankland et al. 1996; Wahab et al. 2005). Unlike mesangial cells, podocytes do not overexpress TGF- β 1 in response to common in

vitro metabolic stimuli, such as high glucose (Iglesias-de la Cruz et al. 2002) and angiotensin II (Ang II) (Chen et al. 2005). Yet albumin load or mechanical strain increases the levels of TGF- β 1 and Ang II, as well as TGF- β type I, II and III receptors in cultured podocytes (Abbate et al. 2002; Dessapt et al. 2009; Durvasula et al. 2004).

Increased intraglomerular pressure results in cellular strain and perpetuates further damage to the podocytes in progressive glomerular disease, eventually leading to glomerulosclerosis (Kriz et al. 1998). The less cross-linked and possibly more elastic physical properties of the GBM in some podocyte diseases may subject the podocytes to elevated biomechanical strain even under normal glomerular blood pressure. As the disease progresses and nephron mass is lost, glomerular hypertension develops, further exacerbating the biomechanical strain and the effector functions influenced by it (Meehan et al. 2009). In the remnant kidney model of glomerular capillary hypertension, TGF- β 1 (Abbate et al. 2002) and Ang II type I receptor (Durvasula et al. 2004) are upregulated by podocytes.

Together, an increase in glomerular capillary pressure may stimulate Ang II and TGF- β 1 expression in podocytes through mechanical force injury in progressive podocyte diseases (Lee 2011) (Fig. 2).

5.3 Activation of latent TGF- β by podocytes in chronic glomerular disease

In podocyte diseases, Ang II-induced oxidative stress may activate the latent TGF- β and, subsequently, the TGF- β signaling system in podocytes (Lee 2011) (Fig. 2). Indeed, diabetic podocytopathy seems to be mediated by Ang II (Ziyadeh and Wolf 2008) and oxidative damage (Zheng et al. 2008).

Osteopontin expression strongly correlates with glomerular disease, and is increased specifically in podocytes. Treatment of podocytes with recombinant osteopontin activated the NF- κ B pathway, increased the expression of urokinase-type plasminogen activator (uPA) and MMP-2 and -9, and increased podocyte motility (Lorenzen et al. 2008). Strong expression of uPA protein and mRNA is sometimes observed within crescents (Lee et al. 2001). These observations suggest that damaged podocytes in the diseased glomeruli may release plasmin, MMP-2 and -9 to activate latent TGF- β (Fig. 2).

In human FSGS, expression levels of TGF- β 1, TSP-1 and TGF- β type II receptor mRNAs and proteins as with phosphorylated Smad2/Smad3 are increased by podocytes (Kim et al. 2003), suggesting that TSP-1 may activate TGF- β in podocytes (Fig. 2). In addition, diabetic mediators upregulate the TGF- β type II receptor that both binds the ligand and initiates the signaling cascade, suggesting that the podocyte is primed to respond to TGF- β (Iglesias-de la Cruz et al. 2002; Wolf et al. 2005).

Altogether, podocyte-derived plasmin, MMPs and TSP-1, and particularly Ang II-induced oxidative stress may activate the latent TGF- β in podocytes in diseased glomeruli. The activated TGF- β may bind to its receptor on podocytes, activating the TGF- β /Smad signaling pathway to induce the expression of its target genes, such as connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) (Fig. 2 and 3).

6. Paracrine effector mechanism of CTGF and VEGF for TGF- β to act on mesangial cells

The podocyte TGF- β , the active form of which has a very short half-life in plasma, is unlikely to traverse the GBM to promote sclerosis in the adjacent mesangium. Instead, some TGF- β -induced humoral factors produced by podocytes seem to have fibrogenic effects on mesangial cells (Lee and Song 2009b).

CTGF is a major autocrine growth factor induced by TGF- β . TGF- β 1 induces CTGF mRNA and protein expression in podocytes (Ito et al. 2001) and mesangial cells (Riser et al. 2000). Expression of CTGF mRNA and/or protein in the mesangium and podocytes is upregulated in human chronic glomerular disease (Ito et al. 1998; Wahab et al. 2005). It is increased particularly in the glomeruli of patients with mesangial matrix expansion (Suzuki et al. 2003). Treatment with the CTGF antisense oligonucleotides significantly reduced the mesangial matrix expansion in diabetic mice (Guha et al. 2007). Furthermore, induction of diabetes in podocyte-specific CTGF-transgenic mice results in an increased mesangial CTGF expression with more severe mesangial expansion than diabetic wild-type mice (Yokoi et al. 2008). TGF- β 1 stimulates VEGF expression in podocytes (Iglesias-de la Cruz et al. 2002). VEGF is a potent angiogenic molecule and is detected predominantly in podocytes (Bailey et al. 1999; Wendt et al. 2003). Yet glomeruli are not sites of angiogenesis, possibly because podocytes mainly express VEGF_{165b} protein, which inhibits VEGF₁₆₅-mediated angiogenesis (Cui et al. 2004). VEGF may play an important role in TGF- β 1-induced glomerular fibrosis (Chen et al. 2004, 2005). VEGF overexpression by podocytes led to mesangial expansion (Veron et al. 2010; Zhang et al. 2010). Furthermore, anti-VEGF attenuates the mesangial matrix expansion in diabetic mice (Flyvbjerg et al. 2002).

The dominant production of VEGF-A by podocytes and the localization of its receptor, VEGFR-2, on glomerular endothelial cells suggest that VEGF-A moves across the GBM, opposing the ultrafiltration gradient to move water and solutes from the capillaries into the Bowman's space (Satchell et al. 2006). In fact, about one third of VEGF secreted from

Fig. 3. Hypothetical pathway for mesangial matrix accumulation via activation of TGF- β by podocytes in chronic glomerular disease. The activated TGF- β may bind to its receptor (TGF- β R') on podocytes, activating TGF- β /Smad signaling pathway to induce the overexpression of its target genes, connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF). The CTGF and VEGF secreted from podocytes may reach the capillary lumen and stimulate mesangial cells to produce excessive matrix proteins, culminating in the development of glomerulosclerosis.

podocytes would reach the capillary lumen and accumulate there, supporting the view that VEGF can move against the flow of glomerular filtration (Katavetin and Katavetin 2008). Although it is not clear whether this is also the case for CTGF, the experiments performed by Yokoi et al. (2008) support that possibility.

In summary, TGF- β -induced CTGF and VEGF secretion by podocytes may act as an effector mechanism, necessary for mesangial matrix accumulation in chronic glomerular disease, culminating in the development of glomerulosclerosis (Fig. 3).

7. Conclusions

In chronic mesangial disease, large latent TGF- β complexes secreted by mesangial cells may be stored in the mesangial matrix, from which soluble large latent TGF- β complexes may be released and localized to the podocyte surface. In progressive podocyte disease, by contrast, mechanical pressure or biomechanical strain may upregulate Ang II and TGF- β expression in podocytes. In both chronic mesangial disease and progressive podocyte disease, podocyte-derived plasmin, TSP-1 and ROS, particularly Ang II-induced oxidative stress, seem to be involved in TGF- β activation. Active TGF- β may induce CTGF and VEGF overexpression in podocytes, which may act as a paracrine effector mechanism on mesangial cells to stimulate mesangial matrix synthesis culminating in the development of glomerulosclerosis. In summary, this review provides new mechanistic insights into the role of TGF- β in mesangial matrix synthesis in chronic progressive glomerular disease. Better understanding of the activation of TGF- β signaling and its downstream effectors, CTGF and VEGF, may provide novel tools for the prevention of glomerulosclerosis.

8. References

- Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G (2002) Transforming growth factor- β 1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. *Am J Pathol* 161:2179-2193
- Abdelouahed M, Ludlow A, Brunner G, Lawler J (2000) Activation of platelet transforming growth factor β -1 in the absence of thrombospondin-1. *J Biol Chem* 275:17933-17936
- Abrahamson DR, Hudson BG, Stroganova L, Borza D-B, St. John PL (2009) Cellular origins of type IV collagen networks in developing glomeruli. *J Am Soc Nephrol* 20:1471-1479
- Abrahamson DR, Prettyman AC, Robert B, St John PL (2003) Laminin-1 reexpression in Alport mouse glomerular basement membranes. *Kidney Int* 63:826-834
- Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 63:225-232
- Annes JP, Chen Y, Munger JS, Rifkin DB (2004) Integrin α v β 6-mediated activation of latent TGF- β requires the latent TGF- β - binding protein-1. *J Cell Biol* 165:723-734
- Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGF β activation. *J Cell Sci* 116:217-224

- Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, Yasuhara A, Shikata K, Kanwar YS, Makino H (2005) Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. *J Am Soc Nephrol* 16:3222-3234
- Bailey E, Bottomley MJ, Westwell S, Pringle JH, Furness PN, Feehally J, Brenchley PEC, Harper SJ (1999) Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by nonisotopic in situ hybridization. *J Clin Pathol* 52:735-738
- Barcellos-Hoff MH, Dix TA (1996) Redox-mediated activation of latent transforming growth factor- β 1. *Mol Endocrinol* 10:1077-1083
- Baricos WH, Reed JC, Cortez SL (2003) Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. *Exp Biol Med*. 228:1018-1022
- Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G (2003) Add-on anti-TGF- β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. *J Am Soc Nephrol* 14:1816-1824
- Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN (2004) Podocyte-derived vascular endothelial growth factor mediates the stimulation of α 3(IV) collagen production by transforming growth factor- β 1 in mouse podocytes. *Diabetes* 53:2939-2949
- Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN (2005) Angiotensin II stimulates α 3(IV) collagen production in mouse podocytes via TGF- β and VEGF signaling: implications for diabetic glomerulopathy. *Nephrol Dial Transplant* 20:1320-1328
- Choudhury D, Tuncel M, Levi M (2010) Diabetic nephropathy--a multifaceted target of new therapies. *Discov Med* 10:406-415
- Coffey RJ Jr, Kost LJ, Lyons RM, Moses HL, LaRusso NE (1987) Hepatic processing of transforming growth factor β in the rat. Uptake, metabolism, and biliary excretion. *J Clin Invest* 80:750-757
- Couser WG, Nangaku M (2006) Cellular and molecular biology of membranous nephropathy. *J Nephrol* 19:699-705
- Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998) Thrombospondin-1 is a major activator of TGF- β 1 in vivo. *Cell* 93:1159-1170
- Cui T-G, Foster RR, Saleem M, Mathieson PW, Gillatt DA, Bates DO, Harper SJ (2004) Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. *Am J Physiol Renal Physiol* 286:F767-773
- D'Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. *Am J Kidney Dis* 43:368-382
- Daniel C, Schaub K, Amann K, Lawler J, Hugo C (2007) Thrombospondin-1 is an endogenous activator of TGF- β in experimental diabetic nephropathy in vivo. *Diabetes* 56:2982-2989
- Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, Rupperecht H, Imai E, Hugo C (2003) Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF- β in fibrotic renal disease in the rat in vivo. *Am J Pathol* 163:1185-1192

- Dessapt C, Baradez MO, Hayward A, Dei Cas A, Thomas SM, Viverti G, Gnudi L (2009) Mechanical forces and TGF β 1 reduce podocyte adhesion through α 3 β 1 integrin downregulation. *Nephrol Dial Transplant* 24:2645-2655
- Drummond K, Mauer M (2002) The early natural history of nephropathy in type 1 diabetes. II. Early renal structural changes in type 1 diabetes. *Diabetes* 51:1580-1587
- Durvasula RV, Pettermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. *Kidney Int* 65:30-39
- Edgton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR (2004) Plasmin is not protective in experimental renal interstitial fibrosis. *Kidney Int* 66:68-76
- El Karoui K, Hill GS, Karras A, Moulonguet L, Caudwell V, Loupy A, Bruneval P, Jacquot C, Nochy D (2011) Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. *Kidney Int* 79:643-654
- Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. *Diabetes* 51:3090-3094
- George SJ, Johnson JL, Smith MA, Angelini GD, Jackson CL (2005) Transforming growth factor- β is activated by plasmin and inhibits smooth muscle cell death in human saphenous vein. *J Vasc Res* 42:247-254
- Gewin L, Bulus N, Mernaugh G, Moeckel G, Harris RC, Moses HL, Pozzi A, Zent R (2010) TGF- β receptor deletion in the renal collecting system exacerbates fibrosis. *J Am Soc Nephrol* 21:1334-1343
- Grainger DJ, Frow EK (2000) Thrombospondin 1 does not activate transforming growth factor- β 1 in a chemically defined system or in smooth muscle-cell cultures. *Biochem J* 350:291-298
- Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996) Alport syndrome-clinical phenotypes, incidence, and pathology. *Contrib Nephrol* 117:1-28
- Guha M, Xu Z-G, Tung D, Lanting L, Natarajan R (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. *FASEB J* 21:3355-3368
- Hartner A, Hilgers KF, Bitzer M, Veelken R, Schöcklmann HO (2003) Dynamic expression patterns of transforming growth factor- β (2) and transforming growth factor- β receptors in experimental glomerulonephritis. *J Mol Med* 81:32-42
- Hill C, Flyvbjerg A, Gronbaek H, Petrik H, Hill DJ, Thomas CR, Sheppard MC, Logan A (2000) The renal expression of transforming growth factor- β isoforms and their receptors in acute and chronic experimental diabetes in rats. *Endocrinology* 141:1196-1208
- Hill GS, El Karoui K, Karras A, Mandet C, Van Huyen J-P D, Nochy D, Bruneval P (2011) Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. *Kidney Int* 79:635-642

- Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ (1998) Thrombospondin-1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. *Kidney Int* 53:302-311
- Hyytiäinen M, Penttinen C, Keski-Oja J (2004) Latent TGF- β binding proteins: extracellular matrix association and roles in TGF- β activation. *Crit Rev Clin Lab Sci* 41:233-264
- Ibels LS, Györy AZ (1994) IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. *Medicine* 73:79-102
- Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S (2002) Effects of high glucose and TGF- β 1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. *Kidney Int* 62:901-913
- Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R (1998) Expression of connective tissue growth factor in human renal fibrosis. *Kidney Int* 53:853-861
- Ito Y, Goldschmeding R, Bende RJ, Claessen N, Chand MA, Kleij L, Rabelink TJ, Weening JJ, Aten J (2001) Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. *J Am Soc Nephrol* 12:472-484
- Jobling MF, Mott JD, Finnegan MT, Jurukovski V, Erickson AC, Walian PJ, Taylor SE, Ledbetter S, Lawrence CM, Rifkin DB, Barcellos-Hoff MH (2006) Isoform-specific activation of latent transforming growth factor- β (LTGF- β) by reactive oxygen species. *Radiat Res* 166:839-848
- Kashtan C, Kim Y, Lees GE, Thorner PS, Virtanen I, Miner JH (2001) Abnormal glomerular basement membrane laminins in murine, canine and human Alport syndrome: aberrant laminin α 2 deposition is species independent. *J Am Soc Nephrol* 12:252-260
- Katavetin P, Katavetin P (2008) VEGF inhibition and renal thrombotic microangiopathy. *N Engl J Med* 359:205-206
- Kim HW, Moon KC, Park SY, Hong HK, Lee HS (2002) Differential expression of platelet-derived growth factor and transforming growth factor- β in relation to progression of IgA nephropathy. *Nephrology* 7:S131-S139
- Kim JH, Kim BK, Moon KC, Hong HK, Lee HS (2003) Activation of the TGF- β /Smad signaling pathway in focal segmental glomerulosclerosis. *Kidney Int* 64:1715-1721
- Kim KH, Kim Y, Gubler MC, Steffes MW, Lane PH, Kashtan CE, Crosson JT, Mauer SM (1995) Structural-functional relationships in Alport syndrome. *J Am Soc Nephrol* 5:1659-1668
- Kim TS, Kim JY, Hong HK, Lee HS (1999) mRNA expression of glomerular basement membrane proteins and TGF- β 1 in human membranous nephropathy. *J Pathol* 189:425-430
- Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS (2001) Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. *J Lab Clin Med* 138:59-68

- Koli K, Myllärniemi M, Keski-Oja J, Kinnula VL (2008) Transforming growth factor- β activation in the lung: focus on fibrosis and reactive oxygen species. *Antioxid Redox Signal* 10:333-342
- Koli K, Saharinen J, Hyytiäinen M, Penttinen C, Keski-Oja J (2001) Latency, activation, and binding proteins of TGF- β . *Microsc Res Tech* 52:354-362
- Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Boettinger EP, Klotman PE, Thorgeirsson SS (1996) Transgenic mice with increased plasma levels of TGF- β 1 develop progressive renal disease. *Lab Invest* 74: 991-1003
- Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: Is the podocyte the culprit? *Kidney Int* 54:687-697
- Lawrence DA (2001) Latent TGF- β : An overview. *Mol Cell Biochem* 219:163-170
- Lee HS (2011) Pathogenic role of TGF- β in the progression of podocyte diseases. *Histol Histopathol* 26:107-116
- Lee HS, Choi Y, Lee JS, Yu BH, Koh HI (1989) Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. *Kidney Int* 35:880-886
- Lee HS, Koh HI (1993) Nature of progressive glomerulosclerosis in human membranous nephropathy. *Clin Nephrol* 39:7-16
- Lee HS, Koh HI, Lee HB, Park HC (1987) IgA nephropathy in Korea: a morphological and clinical study. *Clin Nephrol* 27:131-140
- Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, Park SY, Han JS, Kim S, Lee JS (2005) Histological grading of IgA nephropathy predicting renal outcome: revisiting HS Lee's glomerular grading system. *Nephrol Dial Transplant* 20:342-348
- Lee HS, Lim SD (1995) The significance of glomerular hypertrophy in focal segmental glomerulosclerosis. *Clin Nephrol* 44:349-355
- Lee HS, Moon KC, Song CY, Kim BC, Hong HK (2004) Glycated albumin activates PAI-1 transcription through Smad DNA binding sites in mesangial cells. *Am J Physiol Renal Physiol* 287:F665-F672
- Lee HS, Park SY, Moon KC, Hong HK, Song CY, Hong SY (2001) mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis. *Histopathology* 39:203-209
- Lee HS, Song CY (2009a) Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. *Am J Nephrol* 29:62-70
- Lee HS, Song CY (2009b) Differential role of mesangial cells and podocytes in TGF- β -induced mesangial matrix synthesis in chronic glomerular disease. *Histol Histopathol* 24:901-908
- Lee LK, Pollock AS, Lovett DH (1993) Asymmetric origins of the mature glomerular basement membrane. *J Cell Physiol* 157:169-177
- Liu N, Makino T, Nogaki F, Kusano H, Suyama K, Muso E, Honda G, Kita T, Ono T (2004) Coagulation in the mesangial area promotes ECM accumulation through factor V expression in MsPGN in rats. *Am J Physiol Renal Physiol* 287:F612-F620
- Lorenzen J, Shah R, Biser A, Staicu SA, Niranjan T, Garcia AM, Gruenwald A, Thomas DB, Shatat IF, Supe K, Woroniecki RP, Susztak K (2008) The role of osteopontin in the development of albuminuria. *J Am Soc Nephrol* 19:884-890

- Lyons R, Gentry LE, Purchio AF, Moses HL (1990) Mechanism of activation of latent recombinant transforming growth factor- β 1 by plasmin. *J Cell Biol* 110:1361-1367
- Meehan DT, Delimont D, Cheung L, Zallocchi M, Sansom SC, Holzclaw JD, Rao V, Cosgrove D (2009) Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. *Kidney Int* 76:968-976
- Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broadus VC, Nishimura SL (2002) The integrin α v β 8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF- β 1. *J Cell Biol* 157:493-507
- Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D (1999) The integrin α v β 6 binds and activates latent TGF β 1: a mechanism for regulating pulmonary inflammation and fibrosis. *Cell* 96:319-328
- Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A, Shikata K, Makino H (2006) Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. *Diabetes* 55:1666-1677
- Otsuka G, Stempien-Otero A, Frutkin AD, Dichek DA (2007) Mechanisms of TGF- β 1-induced intimal growth. Plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. *Circ Res* 100:1300-1307
- Patek CE, Fleming S, Miles CG, Bellamy CO, Lodomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML (2003) Murine Denys-Drash syndrome: evidence of podocyte dedifferentiation and systemic mediation of glomerulosclerosis. *Hum Mol Genet* 12:2379-2394
- Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. *Am J Kidney Dis* 44:385-401
- Porst M, Daniel C, Plank C, Schocklmann HO, Reinhardt DP, Hartner A (2006) Induction and coexpression of latent transforming growth factor β -binding protein-1 and fibrillin-1 in experimental glomerulonephritis. *Nephron Exp Nephrol* 102:e99-e104
- Remuzzi A, Monaci N, Bonassi ME, Corna D, Zoja C, Mohammed EI, Remuzzi G (1999) Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive Heymann nephritis. *Lab Invest* 79:1501-1510
- Remuzzi G, Schieppati A, Ruggenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. *N Engl J Med* 346:1145-1151
- Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. *J Am Soc Nephrol* 11:25-38
- Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, von Ruhland CJ, O'Hare MJ, Saleem MA, van den Heuvel LP, Mathieson PW (2006) Conditionally immortalized human

- glomerular endothelial cells expressing fenestrations in response to VEGF. *Kidney Int* 69:1633-1640
- Sayers R, Kalluri R, Rodgers KD, Shield III CF, Meehan DT, Cosgrove D (1999) Role for transforming growth factor- β 1 in Alport renal disease progression. *Kidney Int* 56:1662-1673
- Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG (1996) Differential expression of transforming growth factor- β isoforms and receptors in experimental membranous nephropathy. *Kidney Int* 50:116-124
- Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundry V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeny LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R (2011) Risk HLA-DQA1 and PLA₂R1 alleles in idiopathic membranous nephropathy. *N Engl J Med* 364:616-626
- Stein-Oakley AN, Maguire JA, Dowling J, Perry G, Thomson NM (1997) Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. *Kidney Int* 51:195-204
- Strehlau J, Schachter AD, Pavlakis M, Singh A, Tejani A, Strom TB (2002) Activated intrarenal transcription of CTL-effectors and TGF- β 1 in children with focal segmental glomerulosclerosis. *Kidney Int* 61:90-95
- Suzuki D, Toyoda M, Umezono T, Uehara G, Zhang S-Y, Sakai T, Nishina M, Suga T, Endoh M, Yagame M, Sakai H (2003) Glomerular expression of connective tissue growth factor mRNA in various renal diseases. *Nephrology* 8:92-97
- Taipale J, Koli K, Keski-Oja J (1992) Release of transforming growth factor- β 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. *J Biol Chem* 267:25378-25384
- Trevillian P, Paul H, Millar E, Hibberd A, Agrez MV (2004) α v β 6 integrin expression in diseased and transplanted kidneys. *Kidney Int* 66:1423-1433
- Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A (2010) Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. *Kidney Int* 77:989-999
- Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, Mason RM (2005) Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. *Diabetologia* 48:2650-2660
- Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB (1990) Recombinant latent transforming growth factor β 1 has a longer plasma half-life in rats than active transforming growth factor β 1, and a different tissue distribution. *J Clin Invest* 86:1976-1984
- Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM (2003) RAGE drives the development of

- glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. *Am J Pathol* 162:1123-1137
- Whitworth JA, Turner DR, Leibowitz S, Cameron JS (1978) Focal segmental sclerosis or scarred focal proliferative glomerulonephritis? *Clin Nephrol* 9:229-235
- Wolf G, Chen S, Ziyadeh FN (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. *Diabetes* 54:1626-1634
- Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. *Kidney Int* 77:921-927
- Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K, Yoshioka T, Saito Y, Ogawa Y, Kuwabara T, Sugawara A, Nakao K (2008) Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. *Kidney Int* 73:446-455
- Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA (2004) Combining TGF- β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. *Kidney Int* 66:1774-1784
- Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- β and promotes tumor invasion and angiogenesis. *Genes Dev* 14:163-176
- Zhang H, Schin M, Saha J, Burke K, Holzman LB, Filipiak W, Saunders T, Xiang M, Heilig CW, Brosius FC 3rd (2010) Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. *Am J Physiol Renal Physiol* 299: F91-98
- Zhang YZ, Lee HS (1997) Quantitative changes in the glomerular basement membrane components in human membranous nephropathy. *J Pathol* 183:8-15
- Zheng S, Carlson EC, Yang L, Kralik PM, Huang Y, Epstein PN (2008) Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. *J Am Soc Nephrol* 19:2077-2085
- Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP (1998) Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor- β system. *Kidney Int* 53:631-638
- Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor- β antibody in db/db diabetic mice. *Proc Natl Acad Sci USA* 97:8015-8020

- Ziyadeh FN, Sharma K, Ericksen M, Wolf G (1994) Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor- β . *J Clin Invest* 93:536-542
- Ziyadeh FN, Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. *Curr Diabetes Rev* 4:39-45

An Update on Glomerulopathies - Etiology and Pathogenesis

Edited by Prof. Sharma Prabhakar

ISBN 978-953-307-388-0

Hard cover, 276 pages

Publisher InTech

Published online 06, September, 2011

Published in print edition September, 2011

The book has fourteen chapters which are grouped under different sections: Immune System and Glomerulonephritis, Animal Models of Glomerulonephritis, Cytokines and Signalling Pathways, Role of Cells and Organelles in Glomerulonephritis and Miscellaneous. While the purpose of this volume is to serve as an update on recent advances in the etio-pathogenesis of glomerulopathies, the book offers the current and broad based knowledge in the field to readers of all levels in the nephrology community.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Hyun Soon Lee (2011). Role of TGF- β in Mesangial Matrix Accumulation in Chronic Progressive Glomerular Disease, An Update on Glomerulopathies - Etiology and Pathogenesis, Prof. Sharma Prabhakar (Ed.), ISBN: 978-953-307-388-0, InTech, Available from: <http://www.intechopen.com/books/an-update-on-glomerulopathies-etiology-and-pathogenesis/role-of-tgf-in-mesangial-matrix-accumulation-in-chronic-progressive-glomerular-disease>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen